Newman Dignan & Sheerar, Inc. Adaptimmune Therapeutics PLC Transaction History
Newman Dignan & Sheerar, Inc.
- $363 Million
- Q1 2025
A detailed history of Newman Dignan & Sheerar, Inc. transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Newman Dignan & Sheerar, Inc. holds 27,957 shares of ADAP stock, worth $8,107. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,957
Previous 27,957
-0.0%
Holding current value
$8,107
Previous $5,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ADAP
# of Institutions
74Shares Held
114MCall Options Held
77.5KPut Options Held
14.2K-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$7.95 Million0.43% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR23.8MShares$6.89 Million0.16% of portfolio
-
Two Seas Capital LP Rye, NY20.5MShares$5.95 Million0.15% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$4.95 Million0.32% of portfolio
-
Mpm Asset Management LLC Cambridge, MA5.34MShares$1.55 Million1.54% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $47.4M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...